Extrapyramidal symptoms in Wilson's disease are associated with olfactory dysfunction

Movement Disorders

Volumn 21, Issue 9, 2006, Pages 1311-1316

  Muelle, Antje ^a   Reuner, Ulrike ^a   Landis, Basile ^b   Kitzler, Hagen ^a   Reichmann, Heinz ^a   Hummel, Thomas ^a  

^a UNIVERSITY OF DRESDEN MEDICAL SCHOOL   (Germany)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

Olfaction; Wilson's disease

Indexed keywords

COPPER; FLUORODEOXYGLUCOSE F 18; LIVER ENZYME; PENICILLAMINE; TRIENTINE; ZINC;

ADULT; AGED; ARTICLE; BASAL GANGLION; CLINICAL ARTICLE; CLINICAL PROTOCOL; CONTROLLED STUDY; DEGENERATION; DISEASE ASSOCIATION; DISEASE SEVERITY; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; LIVER DISEASE; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; ODOR; OLFACTORY DISCRIMINATION; OLFACTORY SYSTEM; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SCORING SYSTEM; SMELLING DISORDER; WILSON DISEASE;

ADULT; AGED; BASAL GANGLIA; BASAL GANGLIA DISEASES; BLOOD GLUCOSE; CHROMOSOME ABERRATIONS; COPPER; EXTRAPYRAMIDAL TRACTS; FEMALE; FLUORODEOXYGLUCOSE F18; GENES, RECESSIVE; HEPATOLENTICULAR DEGENERATION; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEURODEGENERATIVE DISEASES; OLFACTION DISORDERS; OLFACTORY PATHWAYS; PARKINSONIAN DISORDERS; POSITRON-EMISSION TOMOGRAPHY; SENSORY THRESHOLDS; STATISTICS;

EID: 33750298075     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.20989     Document Type: Article

References (47)

1. Duchen LW, Jacobs J. Nutritional deficiencies and metabolic disorders. In: Adams JH, Duchen LW, editors. Greenfield's Neuropathology. 5th ed. London: Edward Arnold; 1992, p 838-841.
2. Roh JK, Lee TG, Wie BA. Initial and follow up brain MR findings and correlation with the clinical course in Wilson's disease. Neurology 1994;44:1064-1068.
3. Aisen A, Martel W, Gabrielsen T. Wilson disease of the brain: MR imaging. Radiology 1985;157:137-141.
4. Yuh WTC, Flickinger FW. Unusual MR findings in CNS Wilson's disease [letter]. AJR Am J Roentgenol 1988;151:834.
5. Kunath B, Renner U. Diagnostik und Therapie bei Morbus Wilson. Akt Neurol 2003;30:18-26.
6. Hermann W, Barthel H, Hesse S, et al. Comparison of clinical types of Wilson's disease and glucose metabolism in extrapyramidal brain regions. J Neurol 2002;249:896-901.
7. Westermark K, Tedroff J, Thuomas KA, et al. Neurological Wilson's disease studied with magnetic resonance imaging and with positron emission tomography using dopaminergic markers. Mov Disord 1995;10:596-603.
8. Jeon B, Kim JM, Jeong JM, et al. Dopamine transporter imaging with [123J]-beta-CIT demonstrates presynaptic damage in Wilson's disease. J Neurol Neurosurg Psychiatry 1998;65:60-64.
9. Ansari KA, Johnson A. Olfactory function in patients with Parkinson's disease. J Chron Dis 1975;28:493-497.
10. Doty RL, Deems D, Steller S. Olfactory dysfunction in Parkinson's disease: a general deficit unrelated to neurologic signs, disease stage, or disease duration. Neurology 1988;38:1237-1244.
11. Wenning GK, Shephard B, Hawkes C, Petruckevitch A, Lees A, Quinn N. Olfactory function in atypical parkinsonian syndromes. Acta Neurol Scand 1995;91:247-250.
12. Hawkes CH, Shephard BC, Daniel SE. Olfactory dysfunction in Parkinson's disease. J Neurol Neurosurg Psychiatry 1997;62:436-446.
13. Mesholam RI, Moberg PJ, Mahr RN, Doty RL. Olfaction in neurodegenerative disease: a meta-analysis of olfactory functioning in Alzheimer's and Parkinson's diseases. Arch Neurol 1998; 55:84-90.
14. Doty RL, Reyes P, Gregor T. Presence of both odor identification and detection deficits in Alzheimer's disease. Brain Res Bull 1987;18:597-600.
15. Liberini P, Parola S, Spano PF, Antonini L. Olfactory dysfunction in dementia associated with Lewy bodies. Parkinsonism Relat Disord 1999;5:30.
16. Moberg PJ, Pearlson GD, Speedie LJ, Lipsey JR, Strauss ME, Folstein SE. Olfactory recognition: differential impairments in early and late Huntington's and Alzheimer's disease. J Clin Exp Neuropsychol 1987;9:650-664.
17. Nordin S, Paulsen JS, Murphy C. Sensory- and memory-mediated olfactory dysfunction in Huntington's disease. J Int Neuropsychol Soc 1995;1:281-290.
18. Mueller A, Müngersdorf A, Reichmann B, Strehle G, Hummel T. Olfactory function in Parkinsonian syndromes. J Clin Neurosci 2002; 9:521-524.
19. Ruiz DV. Wilson's disease and skunks?? The copper connection. Wilson's Disease Association Newsletter. 1997.
20. Hummel T, Sekinger B, Wolf S, Pauli E, Kobal G. "Sniffin' Sticks": olfactory performance assessed by the combined testing of odor identification, odor discrimination and olfactory threshold. Chem Senses 1997;22:39-52.
21. Kobal G, Klimek L, Wolfensberger M, et al. Multicenter investigation of 1,036 subjects using a standardized method for the assessment of olfactory function combining tests of odor identification, odor discrimination, and olfactory thresholds. Eur Arch Otorhinolaryngol 2000;257:205-211.
22. Keiser HR, Henkin RI, Bartter FC, Sjoerdsma A. Loss of taste during therapy with penicillamine. JAMA 1968;203:231-233.
23. Alanen A, Komu M, Penttinen M, Leino R. Magnetic resonance imaging and proton MR spectroscopy in Wilson's disease. Br J Radiol 1999;72:749-756.
24. Magalhaes AC, Caramelli P, Menezes JR, et al. Wilson's disease: MRI with clinical correlation. Neuroradiology 1994;36:97-100.
25. Prayer L, Wimberger D, Kramer J, Grimm G, Oder W, Imhof H. Cranial MRI in Wilson's disease. Neuroradiology 1990;32:211-214.
26. Linne T, Agatz I, Saaf J, Wahlund LO. Cerebral abnormalities in Wilson's disease as evaluated by ultra-low-field' magnetic resonance imaging and computerized image processing. Magn Reson Imaging 1990;8:819-824.
27. Ikeda K, Sakata C, Nemoto H, Yokoi F, Sunohara N, Iio M. Clinico-radiological correlation of Wilson's disease by magnetic resonance imaging, computed and positron emission tomography. Rinsho Shinkeigaku 1991;31:147-153.
28. King AD, Walshe JM, Kendall BE, et al. Cranial MR imaging in Wilson's disease. AJR Am J Roentgenol 1996;167:1579-1584.
29. Kuwert T, Hefter H, Scholz D, et al. Regional cerebral glucose consumption measured by positron emission tomography in patients with Wilson's disease. Eur J Nucl Med 1902;19:96-101.
30. AWMF-Online. Leitlinien der Deutschen Gesellschaft für Nuklearmedizin: Konsensus - Neuro-PET. 1997. Available at: http://www.uni-duesseldorf.de/AWMF/II/nukl008.html.
31. Kuwert T, Bartenstein P, Grünwald F, et al. Klinische Wertigkeit der Positronen-Emissions-Tomographie in der Neuromedizin. Nervenarzt 1998;69:1045-1060.
32. Schlaug G, Hefter H, Nebeling B, et al. Dopamine D2 receptor binding and cerebral glucose metabolism recover after D-penicillamine-therapy in Wilson's disease. J Neurol 1994;241:577-584.
33. Oder W, Brucke T, Kollegger H, Spatt J, Asenbaum S, Deecke L. Dopamine D2 receptor binding is reduced in Wilson's disease: correlation of neurological deficits with striatal 123J-iodobenzamide binding. J Neural Transm 1996;103:1093-1103.
34. Oertel WH, Tatsch K, Schwarz J. Decrease of D2 receptors indicated by [123J]-iodobenzamide single-photon emission computed tomography relates to neurological deficit in treated Wilson's disease. Ann Neurol 1992;32:743-748.
35. Morgan JP, Preziosi TJ, Bianchine JR. Ineffectiveness of L-dopa as a supplement to penicillamine in a case of Wilson's disease. Lancet 1970;2:659.
36. Snow BJ, Bhatt M, Martin WRW. The nigrostriatal dopaminergic pathway in Wilson's disease studied with positron emission tomography. J Neurol Neurosurg Psychiatry 1991;54:12-17.
37. Huang CC, Chu NS, Yen TC, Wai YY, Lu CS. Dopamine transporter binding in Wilson's disease. Can J Neurol Sci 2003;30:163-167.
38. Berio A. Favorable results from the association of L-dopa, amantadine and penicillamine in a child with Wilson's disease. IRCS 1974;2:1326.
39. Barbeau A, Friesen H. Treatment of Wilson's disease with L-dopa after failure with penicillamine. Lancet 1970; 1: 1180 -1181.
40. Savic I, Gulyas B, Larsson M, Roland P. Olfactory functions are mediated by parallel and hierarchical processing. Neuron 2000;26: 735-745.
41. Royet JP, Plailly J, Delon-Martin C, Kareken DA, Segebarth C. fMRI of emotional responses to odors: influence of hedonic valence and judgment, handedness, and gender. Neuroimage 2003; 20:713-778.
42. Braak H, Rub U, Gai WP, Del Tredici K. Idiopathic Parkinson's disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen. J Neural Transm 2003;110:517-536.
43. Greenfield JG, Poynton FJ, Walshe FMR. On progressive lenticular degeneration (hepatolenticular degeneration). Q J Med 1924; 17:385-405.
44. Scheinberg IH, Sternleib I. Wilson's Disease. Philadelphia: WB Saunders; 1984.
45. Nyberg P, Gottfries CG, Holmgren G. Advanced catecholaminergic disturbances in the brain in a case of Wilson's disease. Acta Neurol Scand 1982;65:71-75.
46. Nagatsu T, Kato T, Nagatsu I. Catecholamine-related enzymes in the brain of patients with parkinsonism and Wilson's disease. Adv Neurol 1979;24:283-292.
47. Mueller A, Abolmaali ND, Hakimi AR, et al. Olfactory bulb volumes in patients with idiopathic Parkinson's disease a pilot study. J Neural Transm 2005;112:1363-1370.